Preclinical patient‐derived modeling of castration‐resistant prostate cancer facilitates individualized assessment of homologous recombination repair deficient disease

The use of mutation analysis of homologous recombination repair (HRR) genes to estimate PARP‐inhibition response may miss a larger proportion of responding patients. Here, we provide preclinical models for castration‐resistant prostate cancer (CRPC) that can be used to functionally predict HRR defec...

Descripción completa

Detalles Bibliográficos
Autores principales: Elsesy, Mohamed E., Oh‐Hohenhorst, Su Jung, Oing, Christoph, Eckhardt, Alicia, Burdak‐Rothkamm, Susanne, Alawi, Malik, Müller, Christian, Schüller, Ulrich, Maurer, Tobias, von Amsberg, Gunhild, Petersen, Cordula, Rothkamm, Kai, Mansour, Wael Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257417/
https://www.ncbi.nlm.nih.gov/pubmed/36694344
http://dx.doi.org/10.1002/1878-0261.13382

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10257417/
https://www.ncbi.nlm.nih.gov/pubmed/36694344
http://dx.doi.org/10.1002/1878-0261.13382

Ejemplares similares